ADMA Biologics ADMA Accrued liabilities
Accrued liabilities at other companies
Other financials
Where this comes from
Reported directly by ADMA Biologics in its filing.
Tagged under the XBRL concept us-gaap:IncreaseDecreaseInAccruedLiabilities.
The official record: ADMA Biologics’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about ADMA Biologics's accrued liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is ADMA Biologics's accrued liabilities?
- ADMA Biologics (ADMA) reported accrued liabilities of $5.11M in Q1 2026.
- How has ADMA Biologics's accrued liabilities changed year-over-year?
- ADMA Biologics's accrued liabilities increased by 312.6% year-over-year, from -$2.4M to $5.11M.
- What is the long-term trend for ADMA Biologics's accrued liabilities?
- Over 4 years (2021 to 2025), ADMA Biologics's accrued liabilities has grown at a -11.1% compound annual growth rate (CAGR), from $8.34M to $5.21M.
- What does accrued liabilities mean?
- Captures the net change in expenses that have been incurred but not yet invoiced or paid. This metric is essential for understanding the company's short-term operational obligations and the timing of cash outflows.